Psoriasis is frequently accompanied by cardiovascular diseases based on the shared immunopathogenic pathway. We determined the effect of IL-17 inhibitor therapies on early-stage atherosclerosis related arterial wall inflammation described by intima-media thickness (IMT) among severe psoriatic patients. Thirty-one severe psoriatic patients were enrolled. 20 received secukinumab and 11 received ixekizumab. Before treatment initiation and 6 after months, the carotid-brachial-femoral IMT, the Psoriasis Area Severity Index (PASI) and quality of life scales Dermatology Life Quality of Index (DLQI), EuroQol Visual Analogue Scale (EQ VAS) were evaluated. After 6 months significant reductions were observed in PASI (p<0.001) from a median value of 18 to 0, in DLQI (p<0.001) from a median value of 17 to 0, in right carotid IMT (p<0.001) from a median value of 1.1 mm to 0.8 mm, in left carotid IMT (p<0.001) from a median value of 1.1 mm to 0.7 mm, in right brachial IMT (p<0.001) from a median value of 0.75 mm to 0.6 mm, in left brachial IMT (p<0.001) from a median value of 0.8 mm to 0.5 mm, in right femoral IMT (p<0.001) from a median value of 0.9 mm to 0.7 mm, and in left femoral IMT (p<0.001) from a median value from 0.8 mm to 0.7 mm. The cumulative area of the non-calcified plaques in all arteries was reduced, though not significantly (p=0.062), from a median value of 3 mm2 to 1.6 mm2. EQ VAS was significantly improved (p<0.001) from a median value of 60 to 90. IL-17 inhibitor therapies effectively reduce vessel inflammation and may have a beneficial long-term effect on cardiovascular complications of systemic inflammation.

ESDR047 - Interleukin-17 inhibitor therapy reduces arterial intima-media thickness in severe psoriasis

50th Annual Meeting of the European Society for Dermatological Research. VIRTUAL MEETING